Cansortium Holdings Revenue, Growth & Competitor Profile

Company Profile & Annual Report for Cansortium Holdings

Access the complete profile.

Cansortium Holdings Fast Facts

Revenue	Over $500 million    See Exact Annual Revenue
Employees	500 - 1,000Exact Company Size
Primary Industry	325411 Medicinal & Botanical Manufacturing
Address	82 Ne 26th Street - Unit 110 Miami, FL 33137

Note: Revenues for privately held companies are statistical evaluations.


Cansortium Holdings's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Cansortium Holdings's annual revenues are Over $500 million (see exact revenue data)
• What industry is the company in?
  • Cansortium Holdings is classified as operating in the Medicinal & Botanical Manufacturing industry, NAICS Code 325411.

Cansortium Holdings Annual Revenue and Growth Rate

Cansortium Holdings	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2023	Over $500 million Details in Premium Report
2022
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Cansortium Holdings's revenues are gauged from an analysis of company filings.

Cansortium Holdings's Income Statement (based on Industry Averages)

Cansortium Holdings P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Investor Activity

Cansortium Holdings has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.

Date	Investors	Percent Raised	Target Size
November 14, 2017	31	79%	$5 MM
Complete list of funding rounds and total amounts in the Company Report

Trademark Applications

Trademark applications show the products and services that Cansortium Holdings is developing and marketing. Cansortium Holdings doesn't have any recent trademark applications, indicating Cansortium Holdings is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
KNOX Pharmaceuticals and nutraceuticals for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis; prescription synthetic narcotics for medical use; pharmaceutical preparations for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis; none of the forgoing containing marijuana or extracts therefrom	07/13/2017
KNOX MEDICAL Pharmaceuticals and nutraceuticals for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis; prescription synthetic narcotics for medical use; pharmaceutical preparations for the treatment of pain, palliative care, nausea and vomiting, wasting syndrome and loss of appetite in AIDS and cancer patients, anorexia nervosa, Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury, epilepsy, pain, arthritides and musculoskeletal disorders, movement disorders, glaucoma, asthma, hypertension, psychiatric disorders, anxiety, depression, sleep disorders, post-traumatic stress disorder, alcohol and opioid withdrawal symptoms, schizophrenia and psychosis, Alzheimer's disease, dementia, inflammation, inflammatory skin diseases, gastrointestinal system disorders, irritable bowel syndrome, inflammatory bowel diseases, diseases of the liver, metabolic syndrome, obesity, diabetes, diseases of the pancreas, anti-neoplastic properties, and atherosclerosis; none of the forgoing containing marijuana or extracts therefrom	05/16/2017

See all trademarks and details in the Full Report.

Market Share of Cansortium Holdings's Largest Competitors

A competitive analysis shows these companies are in the same general field as Cansortium Holdings, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
XYMOGEN	Orlando, FL	100
AVANTI NUTRITIONAL LABORATORIES	Miami Lakes, FL	37
NUTRITION FORMULATORS	Miramar, FL	36
RTPR	Cabot, AR	33
INTEGRATED BOTANICS	Fort Worth, TX	29
COSMAX NBT USA	Garland, TX	29
CJB INDUSTRIES	Valdosta, GA	28
ALTERNATIVE LABORATORIES	Naples, FL	28
S&B PHARMA	Azusa, CA	28

Nearby Competitors

These companies are similar in business line and location to Cansortium Holdings. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
CANSORTIUM HOLDINGS	Miami, FL	100
SOFGEN PHARMACEUTICALS	Aventura, FL	26
NOVEN PHARMACEUTICALS	Miami, FL	21
INNOVA SOFTGEL	Miami, FL	16
03 USA	Miami, FL	14
ORGANABIO	South Miami, FL	6

Future Competition: Cansortium Holdings's Fastest Growing Competitors

These companies are in the same general field as Cansortium Holdings and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)